Identifying effective therapies for the treatment of progressive forms of multiple sclerosis
(MS) is a highly relevant priority and one of the greatest challenges for the global MS …

The prevalence of autoimmune disorders is increasing steadily and there is no permanent
cure available. Immunomodulation through repeated exposure of antigens, known as …

Background: It is well known that the cerebrospinal fluid (CSF) concentrations of free light
chains (FLC) and immunoglobulin G (IgG) are elevated in multiple sclerosis patients (MS) …

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system
(CNS) characterized by neuroinflammation, neurodegeneration and impaired repair …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system and is
considered to be the leading non-traumatic cause of neurological disability in young adults …

Using the term of progressive multiple sclerosis (PMS), we considered a combined
population of persons with secondary progressive MS (SPMS) and primary progressive MS …

Amyloid-β (Aβ) immunotherapy has recently begun to gain considerable attention as a
potentially promising therapeutic approach to reducing the levels of Aβ in the Central …

Chronic inflammatory autoimmune diseases leading to target tissue destruction and
disability are not only causing increase in patients' suffering but also contribute to huge …

Multiple sclerosis (MS) is an autoimmune life-threatening disease, afflicting millions of
people worldwide. Although the disease is non-curable, considerable therapeutic advances …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
mainly affects young adults between 20 and 40years of age and leads to significant …